|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0034802,
umls-concept:C0205179,
umls-concept:C0229671,
umls-concept:C0332293,
umls-concept:C0441889,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1122962,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-10-1
|
|
pubmed:abstractText |
Epidermal growth factor receptor-overexpression reported in colorectal cancer, justifies therapeutic use of EGFR-inhibitors. We have recently conducted a phase II study in 57 patients with EGFR-positive advanced colorectal cancer (ACC) who received gefitinib-FOLFOX6 followed by gefitinib-single agent as maintenance. Main biological objective was to assess sEGFR as surrogate marker of tyrosine kinase inhibition and as predictor of response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/EGFR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
pubmed-author:BiffiRR,
pubmed-author:ChiappaAA,
pubmed-author:Dell'OrtoPP,
pubmed-author:FazioNN,
pubmed-author:MagniEE,
pubmed-author:MonfardiniLL,
pubmed-author:SantoroLL,
pubmed-author:SonzogniAA,
pubmed-author:ZampinoM GMG,
pubmed-author:ZorzinoLL,
pubmed-author:de BraudFF
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
139-48
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18327586-Adenocarcinoma,
pubmed-meshheading:18327586-Adult,
pubmed-meshheading:18327586-Aged,
pubmed-meshheading:18327586-Antineoplastic Agents,
pubmed-meshheading:18327586-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18327586-Colorectal Neoplasms,
pubmed-meshheading:18327586-Disease-Free Survival,
pubmed-meshheading:18327586-Female,
pubmed-meshheading:18327586-Fluorouracil,
pubmed-meshheading:18327586-Humans,
pubmed-meshheading:18327586-Leucovorin,
pubmed-meshheading:18327586-Male,
pubmed-meshheading:18327586-Middle Aged,
pubmed-meshheading:18327586-Neoplasm Proteins,
pubmed-meshheading:18327586-Organoplatinum Compounds,
pubmed-meshheading:18327586-Prognosis,
pubmed-meshheading:18327586-Quinazolines,
pubmed-meshheading:18327586-Receptor, Epidermal Growth Factor,
pubmed-meshheading:18327586-Treatment Outcome,
pubmed-meshheading:18327586-Tumor Markers, Biological
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
|
|
pubmed:affiliation |
Department of Medicine, Medical Care Unit, European Institute of Oncology, Milan, Italy. maria.zampino@ieo.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
